Glutamate receptors as a target for Alzheimer's disease - Are clinical results supporting the hope?

Journal of Neural Transmission, Supplement

Volumn , Issue 62, 2002, Pages 217-225

  Winblad, B ^a,c   Mobius H J ^b   Stoffler A ^b  

^a KAROLINSKA INSTITUTE   (Sweden)

^b MERZ PHARMACEUTICALS GMBH   (Germany)

^c KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

GLUTAMATE RECEPTOR; MEMANTINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; AMINO ACID RECEPTOR BLOCKING AGENT;

ALZHEIMER DISEASE; CLINICAL TRIAL; COGNITION; CONFERENCE PAPER; DEGENERATIVE DISEASE; DRUG SAFETY; DRUG TOLERABILITY; EVIDENCE BASED MEDICINE; EXPERIENCE; GERMANY; HUMAN; NEUROTRANSMISSION; PRIORITY JOURNAL; AGED; METABOLISM; REVIEW;

AGED; ALZHEIMER DISEASE; EXCITATORY AMINO ACID ANTAGONISTS; HUMANS; MEMANTINE; RECEPTORS, GLUTAMATE;

EID: 0036045137     PISSN: 03036995     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-3-7091-6139-5_20     Document Type: Conference Paper

References (30)

1. Barnes CA, Danysz W, Parsons CG (1996) Effects of the uncompetitive NMDA receptor antagonist memantine on hippocampal long-term potentiation, short-term exploratory modulation and spatial memory in awake, freely moving rats. Eur J Neurosci 8: 565-571
2. Cacabelos R, Takeda M, Winblad B (1999) The glutamatergic system and neurodegeneration in dementia: preventive strategies in Alzheimer's disease. Int J Geriatr Psychiatry 14(1): 3-47
3. Danysz W, Parsons CG, Möbius HJ, Stöffler A, Quack G (2000) Neuroprotection and symptomatological action of memantine relevant for Alzheimer's disease - an unified hypothesis on the mechanism of action. Neurotox Res 2(2-3): 85-98
4. Davies P (1999) Challenging the cholinergic hypothesis in Alzheimer disease [editorial]. JAMA 281(15): 1433-1444
5. Ditzler K (1991) Efficacy and tolerability of memantine in patients with dementia syndrome. A double-blind, placebo controlled trial. Arzneimittelforschung 41: 773-780
6. Fratiglioni L, De Ronchi D, Agüero-Torres H (1999) Worldwide prevalence and incidence of dementia. Drugs Ageing 15: 365-375
7. Galasko D, Bennett D, Sano M, Ernesto C, Thomas R, Grundman M, Ferris S (1997) An inventory to assess activities of daily living for clinical trials in Alzheimer's disease. Alzheimers Dis Assoc Disord 11[Suppl 2]: 33-39
8. Galasko DR, Schmitt FA, Jin S, Saxton J, Bennett D, Sano M, Ferris SH (2000) Detailed assessment of cognition and activities of daily living in moderate to severe Alzheimer's disease. Neurobiol Aging 21(1S): 168
9. Görtelmeyer R, Erbler H (1992) Memantine in the treatment of mild to moderate dementia syndrome. A double-blind placebo-controlled study. Arzneimittelforschung/Drug Res 42(7): 904-913
10. Greenamyre J, Young A (1989) Excitatory amino acids and Alzheimer's disease. Neurobiol Aging 10: 593-602
11. Jorm AF, Jolley D (1998) The incidence of dementia: a meta-analysis. Neurology 51(3): 728-733
12. Kornhuber J, Weller M (1997) Psychotogenicity and N-methyl-D-aspartate receptor antagonism: implications for neuroprotective pharmacotherapy. Biol Psychiatry 41(2): 135-144
13. Lancelot E, Beal MF (1998) Glutamate toxicity in chronic neurodegenerative disease. Prog Brain Res 116: 331-347
14. Launer LJ, Hofman A (2000) Frequency and impact of neurologic diseases in the elderly of Europe: a collaborative study of population-based cohorts. Neurology 54[11 Suppl 5]: 1-8
15. Lobo A, Launer LJ, Fratiglioni L, Andersen K, Di Carlo A, Breteler MM, Copeland JR, Dartigues JF, Jagger C, Martinez-Lage J, Soinmen H, Hofman A (2000) Prevalence of dementia and major subtypes in Europe: a collaborative study of population-based cohorts. Neurologic Diseases in the Elderly Research Group. Neurology 54111 Suppl 5]: S4-9
16. Orgogozo JM, Rigaud AS, Stöffler A, Möbius HJ, Forette F (2002) Efficacy and safety of memantine in patients with mild to moderate vascular dementia: a randomized, placebo-controlled trial (MMM 300). Stroke (in press)
17. Palmer AM, Gershon S (1990) Is the neuronal basis of Alzheimer's disease cholinergic or glutamergic? FASEB J 4: 2745-2752
18. Parsons CG, Gruner R, Rozental J, Millar J, Lodge D (1993) Patch clamp studies on the kinetics and selectivity of N-methyl-D-aspartate receptor antagonism by memantine (1-amino-3,5-dimethyladamantan). Neuropharmacology 32(12): 1337-1350
19. Parsons CG, Danysz W, Quack G (1998) Glutamate in CNS disorders as a target for drug development: an update. Drug News Perspect 11(9): 523-569
20. Reisberg B, Windscheif U, Ferris SH, Hingorani VH, Stöffler A, Möbius HJ (2000) Memantine in moderately severe to severe Alzheimer's disease (AD): results of a placebo-controlled 6-month trial. Neurobiol Aging 21(1S): S275
21. Rosen WG, Terry RD, Fuld PA, Katzman R, Peck A (1980) Pathological verification of ischemic score in differentiation of dementias. Ann Neurol 7(5): 486-488
22. Sahin K, Stöffler A, Furtuna P, Rosenwald D, Möbius HJ (2000) Dementia severity and the magnitude of cognitive benefit by memantine treatment. A subgroup analysis of two placebo-controlled clinical trials in vascular dementia. Neurobiol Aging 21(1S): S168
23. Saxton J, McGonigle KL, Swihart AA, Boller F (1993) The Severe Impairment Battery. The University of Pittsburgh of the Commonwealth System of Higher Education (eds) Thames Valley Test Company, Suffolk, pp 1-16
24. Sclan SG, Reisberg B (1992) Functional assessment staging (FAST) in Alzheimer's disease: reliability, validity, and ordinality. Int Psychoger 4[Suppl 1]: 55-69
25. Szatkowski M, Atwell D (1994) Triggering and execution of neuronal death in brain ischaemia: two phases of glutamate release by different mechanisms. Trends Neurosci 17(9): 359-365
26. van der Kam P, Mol F, Wimmers MFHC (1986) [Assessment scale for geriatric patients] Beordelingsschaal voor Oudere Patienten (BOP). Van Loghum Slaterus, The Netherlands
27. Wilcock G, Möbius HJ, Stöffler A, on behalf of the MMM 5000 Group (2002) A double-blind, placebo-controlled multicentre study of memantine in mild to moderate vascular dementia (MMM 500). Int Clin Psychopharmacol (in press)
28. Winblad B, Poritis N (1999) Memantine in severe dementia, results of the M-BEST study (benefit and efficacy in severely demented patients during treatment with memantine). Int J Geriatr Psych 14(2): 135-146
29. Winblad B, Wimo A, Möbius HJ, Fox JM, Fratiglioni L (1999) Severe dementia: a common condition entailing high costs at individual and societal levels. Int J Geriatr Psychiatry 14(11): 911-914
30. Zajaczkowski W, Quack G, Danysz W (1996) Infusion of (+)-MK-801 and memantine - Contrasting effects on radial maze learning in rats with entorhinal cortex lesion. Eur J Pharmacol 296: 239-246